Chronic Kidney Disease & Nephroprotective Pharmacology
This isn’t just watching numbers fall — it’s protecting nephrons, slowing scarring, and buying time. Every result, every dose, every check matters.
eGFR staging, proteinuria, why ACE inhibitors protect kidneys long-term, and managing anaemia, bone disease, and fluid balance.
Understanding CKD — Slow, Silent, Progressive
Unlike AKI which happens fast and can reverse, Chronic Kidney Disease means damage lasting 3+ months — often permanent. Diabetes and high blood pressure are the two biggest causes. Over years, high pressure inside the tiny filtering units tears the delicate barrier. Protein leaks into urine — and that protein itself poisons the kidney tissue, causing scarring. The remaining healthy nephrons work harder, pressure rises further, and the damage accelerates. It’s a vicious cycle — and early detection is the only way to break it.
Staging — eGFR & Albuminuria
We stage CKD from 1 to 5 using estimated Glomerular Filtration Rate — how much blood the kidneys filter each minute. We also look at the albumin-to-creatinine ratio (ACR) — protein leakage is just as important as the eGFR number itself:
- Stage 1: eGFR ≥ 90 — kidney damage present but function still normal
- Stage 2: eGFR 60–89 — mild reduction, damage usually visible on tests
- Stage 3a: eGFR 45–59 — moderate drop; 3b: 30–44 — worsening function
- Stage 4: eGFR 15–29 — severe; planning for dialysis or transplant
- Stage 5: eGFR < 15 — established kidney failure; replacement therapy needed
Checking urine for albumin is as important as checking eGFR. Persistent protein leakage drives scarring and predicts both faster kidney decline and higher heart disease risk. Don’t skip that sample.
Why We Give Drugs That ‘Lower Kidney Function’
It seems contradictory — we saw in the AKI guide that ACE inhibitors can worsen acute kidney injury. So why are they the first line protection in chronic kidney disease? Because the mechanism is exactly what saves the kidney long-term.
ACE Inhibitors & ARBs — Ramipril, Lisinopril, Candesartan
How they work: Inside the filter, blood enters through one vessel and leaves through another. Angiotensin II squeezes the exit vessel tight — raising pressure inside the filter. ACE inhibitors relax that exit vessel. Pressure drops. The delicate filter stops being torn apart. Protein leakage falls. Scarring slows.
What to expect: A small rise in creatinine (up to 25%) when starting or increasing dose is normal and expected — it means the pressure has come down. Don’t stop it without speaking to the team. Watch potassium levels closely — that’s the real danger. If creatinine rises more than 30% or potassium spikes — review urgently.
SGLT2 Inhibitors — Dapagliflozin, Empagliflozin
Originally diabetes drugs, these now protect kidneys whether the patient has diabetes or not. They reduce the workload on the nephrons, lower pressure inside the filters, and slow decline. They are now standard care in many CKD patients alongside blood pressure control.
When Function Falls — Managing the Complications
As kidneys fail, they don’t just stop filtering waste. They stop making hormones, balancing minerals, and regulating blood. These are the problems you’ll see and help manage on the ward:
- Renal Anaemia: Kidneys make the hormone erythropoietin that tells bone marrow to make red blood cells. Fewer cells = profound tiredness, breathlessness, poor appetite. Treated with iron supplements and EPO injections.
- Bone & Mineral Disease: Phosphate builds up; vitamin D can’t be activated. Bones weaken; parathyroid glands overwork. Phosphate binders taken with every meal stop absorption — timing matters. They must be eaten with food to work.
- Fluid & Electrolytes: Less urine output = swelling, higher blood pressure, breathlessness. Potassium builds silently — dangerous for the heart. Fluid limits, reduced salt, careful monitoring — and knowing when to call the team.
📖 Trusted Guidelines & References
Standards to cite and share — updated and current:
- NICE NG203 — Chronic Kidney Disease (updated Nov 2021, last reviewed Aug 2025) — UK framework for diagnosis, staging, monitoring, and drug protection.
- KDIGO — International CKD Guidelines — Global gold standard for evaluation, blood pressure targets, and management pathways.
- British National Formulary (BNF) — Renal dose adjustments, ACE inhibitor monitoring, and potassium management.
Written by: Daniel Hancock, Registered Nurse
Focus: Renal protection, chronic disease management, ward monitoring
Published: September 2026 | Last reviewed: September 2026
For: UK student nurses — supervised learning only
⚠️ NICE NG203 is the current UK reference. Always confirm dose changes and monitoring plans with the medical team — especially when starting or adjusting ACE inhibitors or SGLT2 inhibitors.